Buprenorphine Use for Opioid Bowel Dysfunction Without Analgesia Loss

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for opioid-induced adverse pharmacodynamic responses, such as bowel dysfunction and other side effects, are associated with significant risks and side effects, necessitating a safer and more effective method to prevent or treat these issues.

Innovation Solution

Administering buprenorphine, either alone or concurrently with other opioids, to mitigate opioid-induced adverse pharmacodynamic responses by targeting peripheral opioid receptors, thereby minimizing side effects while maintaining analgesic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If opioid antagonists such as naloxone and naltrexone are administered to suppress receptors causing bowel dysfunction, then gastrointestinal motility is improved, but the desired analgesic effect of the opioid is reversed

Engineering Contradiction:

Improvegastrointestinal motilityVSAvoidanalgesic effect

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The invention divides the treatment approach into two separate components: (1) administration of the opioid for analgesia, and (2) administration of a peripherally restricted opioid or mu-opioid receptor antagonist specifically targeting gastrointestinal receptors. This segmentation allows independent optimization of each function without mutual interference.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs agents with selective peripheral restriction properties that concentrate their action in the gastrointestinal tract rather than systemically. This local quality ensures that analgesic effects are preserved in the CNS while gastrointestinal side effects are treated peripherally.

Inventive Principle:

Principle #3Local quality

2Ease of operation

If laxatives such as bisacodyl and psyllium are administered to treat bowel dysfunction, then gastrointestinal motility is improved, but severe side effects such as dehydration and bowel obstruction occur

Engineering Contradiction:

Improvegastrointestinal motilityVSAvoiddehydration and bowel obstruction

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The invention converts the harmful side effect of opioid-induced constipation into a treatable condition by using peripherally restricted opioids that specifically target gastrointestinal mu-receptors. This approach treats the constipation mechanism directly rather than forcing stool passage, thereby eliminating the harmful side effects of traditional laxatives while maintaining therapeutic benefit.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of operation

If prokinetic agents such as metoclopramide are administered to improve gastrointestinal motility, then bowel dysfunction is treated, but extrapyramidal effects such as acute dystonic reactions, pseudoparkinsonism or akathisia occur

Engineering Contradiction:

Improvegastrointestinal motilityVSAvoidextrapyramidal effects

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The invention introduces peripherally restricted opioids as intermediary agents that specifically target gastrointestinal mu-opioid receptors. These intermediaries treat the underlying opioid-induced constipation mechanism without activating dopamine receptors in the CNS, thereby avoiding extrapyramidal side effects while effectively improving gastrointestinal motility.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12582647B2Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Publication Date: 2026.03.24 PURDUE PHARMA LP

AI summary

Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.